• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Type 2 Diabetes, on Insulin, Not at Goal: 2 Case Studies

Slideshow

Meet 2 type 2 diabetes patients on multiple antihyperglycemics but still not meeting the ADA recommended A1c goal of 7%. What are the next best steps?

The 2 patients with type 2 diabetes in these short cases will be familiar to many primary care physicians - they are both on multiple antihyperglycemic medications and appear to be adherent to their regimens and yet are still above the American Diabetes Association recommended A1c goal of 7%.

Consider the options for next steps with the short history provided by Dr Sudipa Sarkar in mind. What's the next best step?

Related Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Related Content
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort / image credit ASCVD: ©Rasi/stock.adobe.com

Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort

April 16th 2024
Article

Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D / image Mikhail Kosiborod, MD St Luke's Mid America Heart institute

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D

April 8th 2024
Article

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose / image credit: ©New Africa/AdobeStock

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose

April 4th 2024
Article

Your daily dose of the clinical news you may have missed.

Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD / Image credit: ©PH-HY/AdobeStock

Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD

March 27th 2024
Article

Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.

© 2024 MJH Life Sciences

All rights reserved.